[Towards customized therapy for non small cell lung cancer].
Despite the development of new chemotherapy regimens, including platinum-containing combinations, the prognosis of NSCLC remains very poor. Advances in the understanding of cancer biology and more specifically, of cell signalling pathways have led to the identification of several potential molecular targets and to the development of new agents directed against these targets. The most advanced molecular therapies target the EGF (epidermal growth factor) receptor and the angiogenesis pathway. Despite this progress, treatment efficacy (molecularly-targeted therapy or chemotherapy) appears to be very heterogeneous across patients. The current challenge is to be able to define the most relevant patient-tailored treatment, based on clinical, histological or biological markers, in order to improve the benefit and tolerance of antitumor treatments. Discovering new prognostic or predictive biomarkers for lung cancer is one of the main objectives of translational cancer research.
Planchard
David
D
Département de médecine-oncologie thoracique, Institut Gustave-Roussy, Villejuif, France. david.planchard@igr.fr
Besse
Benjamin
B
D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D004268:DNA-Binding Proteins / Q000378:metabolism; D019008:Drug Resistance, Neoplasm; D004720:Endonucleases / Q000378:metabolism; D066246:ErbB Receptors / Q000235:genetics; D005784:Gene Amplification; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009363:Neoplasm Proteins / Q000378:metabolism; D012262:Ribonucleoside Diphosphate Reductase; D014404:Tubulin / Q000378:metabolism; D025521:Tumor Suppressor Proteins / Q000378:metabolism
D004268:DNA-Binding Proteins; D009363:Neoplasm Proteins; D014404:Tubulin; D025521:Tumor Suppressor Proteins; C475286:RRM1 protein, human; D012262:Ribonucleoside Diphosphate Reductase; D066246:ErbB Receptors; C071447:ERCC1 protein, human; D004720:Endonucleases